AACC uses Cookies to ensure the best website experience. Continuing without changing Cookie settings assumes you consent to our use of cookies on this device. You can change these settings at any time, but that may impair functionality on our websites. Review our cookie and privacy policy


Features


Despite some of the challenges of RNA Sequencing, evidence shows that this method of analysis is solving undiagnosed cases for which DNA Sequencing alone was inconclusive.
Diabetes monitoring technologies are being adopted rapidly even as they continue to evolve. Despite this popularity, however, the rise of continuous glucose monitors and related sensor, pump, and information technologies is not without challenges, as both users and clinicians struggle to keep up with data and practical implementation dilemmas.
In Anaheim, California, the 71st AACC Annual Scientific Meeting featured 835 exhibitors and attracted around 20,000 professionals from around the globe. The four-day event offered a window into the extraordinary changes shaping the future of laboratory medicine.

Ask the Expert


Bench Matters


A force multiplier is a factor that dramatically increases the power of the forces or resources at a team’s disposal. On the laboratory medicine front, there is much to gain by strategically implementing force multipliers to maximize limited resources and minimize productivity constraints

Federal Insider


Industry Playbook


Laboratory Stewardship


Seattle Children’s Hospital Medical Director, Mike Astion, discusses how clinicians handle medical tests that lack evidence on whether they are ready to be used in laboratories.

Regulatory Roundup


Traditionally, the process for testing Lyme disease has involved immunoblots, which lead to longer turnaround times for results. The FDA has now cleared four tests developed by Zeus Scientific that eliminate immunoblots, while still providing an effecting testing approach.

The Sample


The U.S. Preventive Services Task Force has released updated recommendations for testing women for BRCA mutations associated with increased risk of cancer. Women who have either a personal or family history of breast, ovarian, tubal, or peritoneal cancers or Ashkenazi Jewish heritage are all recommended to be screened for their…